Soligenix Awarded Multimillion BARDA Contract for OrbeShield - - BioPharm International

ADVERTISEMENT

Soligenix Awarded Multimillion BARDA Contract for OrbeShield



Soligenix, a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures (MCMs), has been awarded a contract valued at up to $26.3 million by the US Department of Health and Human Service’s Biomedical Advanced Research and Development Authority (BARDA). The contract is for the advanced preclinical and manufacturing development of OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP) as a MCM for the treatment of gastrointestinal acute radiation syndrome (GI ARS).

The potential five-year contract contains a two-year base period, with two contract options that would extend the contract an additional three years. The total award will support the preclinical and manufacturing development activities necessary to navigate and complete the FDA approval process for use of OrbeShield to treat GI ARS.

Source: Soligenix

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Panel Unanimously Backs Secukinumab for the Treatment of Psoriasis
October 22, 2014
Amgen Sues Sanofi and Regeneron over Patent for mAb Targeting PCSK9
October 20, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
AbbVie/Shire Deal Officially Off
October 20, 2014
BioReliance Introduces New Predictive Assays
October 17, 2014
Author Guidelines

Click here